Trials / Completed
CompletedNCT00197613
The Adult Antiretroviral Treatment and Resistance Study (Tshepo)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 650 (planned)
- Sponsor
- Harvard School of Public Health (HSPH) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The "Adult Antiretroviral Treatment and Resistance Study," hereafter referred to as "The Tshepo Study," is the first large-scale research study of antiretroviral therapy to treat AIDS and HIV infection in Botswana. The Tshepo Study is an open-label, randomized study comparing: (1) the rate of development and specific types of drug resistance mutations with various antiretroviral combination therapies to HIV-1C, the subtype of HIV found in southern Africa, and (2) the short and long-term effectiveness of two operational modifications of Directly Observed Therapy (DOT) medication adherence strategies for antiretroviral therapy. Specifically, treatment follow-up via the Standard of Care, the national standard of care as it evolves in Botswana, with intensive clinic-based follow up including regular adherence education sessions, will be compared to Community-Based Directly Observed Therapy (Com-DOT). Com-DOT involves the SOC with added community or family-based DOT. This Com-DOT component would involve a trained, community or family-based Medication Partner ("mopati") who observes the patient take his or medications daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | (A) zidovudine, lamivudine and nevirapine | |
| DRUG | (B) zidovudine, lamivudine and efavirenz | |
| DRUG | (C) zidovudine, didanosine, and nevirapine | |
| DRUG | (D) zidovudine, didanosine, and efavirenz | |
| DRUG | (E) stavudine, lamivudine, and nevirapine | |
| DRUG | (F) stavudine, lamivudine and efavirenz | |
| PROCEDURE | Adherence Strategy Standard of Care (SOC) | |
| PROCEDURE | Adherence Strategy Community-Based DOT |
Timeline
- Start date
- 2002-12-01
- Completion
- 2007-12-01
- First posted
- 2005-09-20
- Last updated
- 2012-09-17
Locations
1 site across 1 country: Botswana
Source: ClinicalTrials.gov record NCT00197613. Inclusion in this directory is not an endorsement.